Company performance
Current Price
as of Feb 07, 2025$4.11
P/E Ratio
N/A
Market Cap
$2.15M
Description
Revelation Biosciences, Inc. is a clinical-stage life sciences company, which focuses on the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.
Metrics
Overview
- HQSan Diego, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerREVB
- Price$4.11-3.75%
Trading Information
- Market cap$2.15M
- Float99.97%
- Average Daily Volume (1m)593,147
- Average Daily Volume (3m)3,338,478
- EPS-$268.08
Company
- RevenueN/A
- Rev growth (1yr)N/A
- Net income-$2.24M
- Gross marginN/A
- EBITDA marginN/A
- EBITDA-$1.79M
- EV-$4.26M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
- P/B0.41
- Debt/EquityN/A